Open AccessComparative Treatment Patterns, Resource Utilization, and Costs in Stimulant-Treated Children with ADHD Who Require Subsequent Pharmacotherapy with Atypical Antipsychotics Versus Non-Antipsychotics
Author(s) -
Vanja Sikirica,
Steven R. Pliszka,
Keith A. Betts,
Paul Hodgkins,
Thomas M. Samuelson,
Jipan Xie,
M. Haim Erder,
Ryan Dammerman,
Brigitte Robertson,
Eric Q. Wu
Publication year - 2012
Publication title -
journal of managed care pharmacy
Language(s) - English
Resource type - Journals
eISSN - 1944-706X
pISSN - 1083-4087
DOI - 10.18553/jmcp.2012.18.9.676
Subject(s) - medicine , atomoxetine , risperidone , stimulant , aripiprazole , antipsychotic , quetiapine , methylphenidate , psychiatry , ziprasidone , olanzapine , thioridazine , attention deficit hyperactivity disorder , pediatrics , schizophrenia (object oriented programming) , chlorpromazine
Although not indicated for attention-deficit/hyperactivity disorder (ADHD), atypical antipsychotics (AAPs) are commonly prescribed for children with ADHD. The treatment patterns, resource utilization, and costs associated with AAPs relative to non-antipsychotic medications have not been evaluated for children with ADHD.